The Delhi High Court has made a significant decision, allowing Sun Pharma to manufacture and export its version of semaglutide, a key ingredient in popular diabetes and weight-loss drugs like Ozempic and Wegovy.
This ruling comes just a week after a similar decision was made in favor of Dr Reddy’s Lab, indicating a shift in India’s position as a global supplier of obesity and diabetes medications. However, both companies are not allowed to sell these drugs in India until the patent expires in March.
The Danish drugmaker, Novo Nordisk, holds two patents on semaglutide in India. One patent has already expired, while the other is set to expire in March 2026. The expired patent has led to increased interest from Indian pharmaceutical companies in the GLP-1 market, which has seen rapid global growth due to demand for weight-loss therapies.
This decision opens up export opportunities for Sun Pharma in markets where Novo Nordisk does not have patent protection. The company can now leverage these opportunities to expand its presence in the global diabetes and weight-loss drugs market. The GLP-1 segment is a key area of focus, with semaglutide, Ozempic, and Wegovy being notable drugs in this category.
Some key points to note about this ruling include:
Download the TradeKaizen app to practice F&O trading with real-time market data anytime, anywhere.
Get it on Google PlayConnect with fellow traders, share strategies, and improve your trading skills in our Telegram group.
Join Telegram